Transaction in Own Shares

PureTech Health PLC
22 December 2023
 

22 December 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:             

21 December 2023



Number of ordinary shares purchased:

61,072



Highest price paid per share:

154.20p



Lowest price paid per share:

147.00p



Volume weighted average price paid per share:

150.69p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 17,578,713 ordinary shares in treasury and has 271,889,446 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 271,889,446 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

21/12/2023

08:18:42

578

154

BATE

00383349019TRLO0.1.1

21/12/2023

08:18:42

358

154.2

AQXE

00383349018TRLO0.1.1

21/12/2023

08:18:42

578

154.2

CHIX

00383349020TRLO0.1.1

21/12/2023

08:18:42

189

154

TRQX

00383349021TRLO0.1.1

21/12/2023

08:18:42

578

154.2

XLON

00383349022TRLO0.1.1

21/12/2023

08:27:56

578

153.8

CHIX

00383350179TRLO0.1.1

21/12/2023

08:27:56

578

153.8

XLON

00383350180TRLO0.1.1

21/12/2023

08:28:53

701

153.4

XLON

00383350279TRLO0.1.1

21/12/2023

09:11:06

124

153.4

XLON

00383355130TRLO0.1.1

21/12/2023

09:24:21

578

153.8

CHIX

00383357236TRLO0.1.1

21/12/2023

09:24:21

30

153.6

XLON

00383357237TRLO0.1.1

21/12/2023

09:24:21

366

153.6

CHIX

00383357238TRLO0.1.1

21/12/2023

09:24:21

140

153.6

CHIX

00383357239TRLO0.1.1

21/12/2023

09:24:21

72

153.6

CHIX

00383357240TRLO0.1.1

21/12/2023

09:24:21

1704

153.6

XLON

00383357241TRLO0.1.1

21/12/2023

09:27:51

506

153.4

BATE

00383357657TRLO0.1.1

21/12/2023

09:27:51

358

153.4

AQXE

00383357656TRLO0.1.1

21/12/2023

09:27:51

72

153.4

BATE

00383357658TRLO0.1.1

21/12/2023

09:27:51

189

153.4

TRQX

00383357659TRLO0.1.1

21/12/2023

09:40:15

1734

153

XLON

00383359942TRLO0.1.1

21/12/2023

09:48:44

578

152

CHIX

00383360843TRLO0.1.1

21/12/2023

09:48:44

2312

152

XLON

00383360844TRLO0.1.1

21/12/2023

10:00:49

51

151

XLON

00383362047TRLO0.1.1

21/12/2023

10:00:49

2261

151

XLON

00383362048TRLO0.1.1

21/12/2023

10:03:39

578

150

XLON

00383362645TRLO0.1.1

21/12/2023

10:03:39

909

150

XLON

00383362646TRLO0.1.1

21/12/2023

10:19:54

34

149.2

XLON

00383365810TRLO0.1.1

21/12/2023

10:20:59

16

149.2

XLON

00383365933TRLO0.1.1

21/12/2023

10:21:03

3

149.2

XLON

00383365938TRLO0.1.1

21/12/2023

10:34:13

9

149.2

XLON

00383367570TRLO0.1.1

21/12/2023

10:55:09

578

149.6

CHIX

00383370623TRLO0.1.1

21/12/2023

10:55:09

358

149.2

AQXE

00383370624TRLO0.1.1

21/12/2023

10:55:09

51

149.2

XLON

00383370625TRLO0.1.1

21/12/2023

10:55:09

684

149.2

CHIX

00383370627TRLO0.1.1

21/12/2023

10:55:09

578

149.2

CHIX

00383370626TRLO0.1.1

21/12/2023

10:55:09

1043

149.2

XLON

00383370628TRLO0.1.1

21/12/2023

10:55:09

578

149.2

XLON

00383370629TRLO0.1.1

21/12/2023

10:58:19

578

149

BATE

00383371013TRLO0.1.1

21/12/2023

10:58:19

240

149

BATE

00383371014TRLO0.1.1

21/12/2023

10:58:19

189

149.2

TRQX

00383371015TRLO0.1.1

21/12/2023

10:58:19

1734

148.6

XLON

00383371016TRLO0.1.1

21/12/2023

12:16:48

472

148.8

CHIX

00383378822TRLO0.1.1

21/12/2023

12:16:48

578

148.8

XLON

00383378823TRLO0.1.1

21/12/2023

12:16:48

590

148.8

XLON

00383378825TRLO0.1.1

21/12/2023

12:16:48

1156

148.8

XLON

00383378824TRLO0.1.1

21/12/2023

12:16:49

1493

148.8

XLON

00383378826TRLO0.1.1

21/12/2023

12:16:49

267

148.8

XLON

00383378827TRLO0.1.1

21/12/2023

12:18:16

712

148.8

XLON

00383378977TRLO0.1.1

21/12/2023

12:18:16

267

148.8

XLON

00383378978TRLO0.1.1

21/12/2023

12:25:17

4

148.8

XLON

00383379636TRLO0.1.1

21/12/2023

12:50:13

358

148

AQXE

00383382990TRLO0.1.1

21/12/2023

12:50:13

189

148

TRQX

00383382992TRLO0.1.1

21/12/2023

12:50:13

474

148

BATE

00383382991TRLO0.1.1

21/12/2023

12:50:13

2447

148

XLON

00383382993TRLO0.1.1

21/12/2023

12:57:42

1734

147

XLON

00383383913TRLO0.1.1

21/12/2023

12:58:28

578

147.4

CHIX

00383383980TRLO0.1.1

21/12/2023

12:58:28

408

147.4

XLON

00383383981TRLO0.1.1

21/12/2023

12:58:28

170

147.4

XLON

00383383982TRLO0.1.1

21/12/2023

13:58:28

152

149.2

XLON

00383393821TRLO0.1.1

21/12/2023

14:13:52

213

149.8

CHIX

00383397373TRLO0.1.1

21/12/2023

14:13:52

671

149.8

CHIX

00383397374TRLO0.1.1

21/12/2023

14:49:09

90

152.2

XLON

00383407261TRLO0.1.1

21/12/2023

14:53:06

578

151.6

CHIX

00383408592TRLO0.1.1

21/12/2023

14:53:06

1242

151.6

XLON

00383408593TRLO0.1.1

21/12/2023

14:53:06

508

151.4

BATE

00383408594TRLO0.1.1

21/12/2023

14:53:06

578

151.4

BATE

00383408595TRLO0.1.1

21/12/2023

14:53:10

189

151.2

TRQX

00383408628TRLO0.1.1

21/12/2023

14:53:10

213

151.4

AQXE

00383408631TRLO0.1.1

21/12/2023

14:53:10

503

151.6

AQXE

00383408632TRLO0.1.1

21/12/2023

14:53:20

35

151.2

XLON

00383408681TRLO0.1.1

21/12/2023

14:53:26

9

151.2

XLON

00383408710TRLO0.1.1

21/12/2023

14:53:26

36

151.2

XLON

00383408711TRLO0.1.1

21/12/2023

14:56:03

559

151.2

XLON

00383409806TRLO0.1.1

21/12/2023

14:56:09

4

151

AQXE

00383409842TRLO0.1.1

21/12/2023

15:16:43

1356

151.4

CHIX

00383417663TRLO0.1.1

21/12/2023

15:32:30

1696

151.4

CHIX

00383423441TRLO0.1.1

21/12/2023

15:33:12

1026

151.6

CHIX

00383423731TRLO0.1.1

21/12/2023

15:33:22

31

151.6

CHIX

00383423789TRLO0.1.1

21/12/2023

15:33:39

213

151.6

CHIX

00383423963TRLO0.1.1

21/12/2023

15:33:55

213

151.6

CHIX

00383424105TRLO0.1.1

21/12/2023

15:37:30

213

151.6

CHIX

00383426131TRLO0.1.1

21/12/2023

15:37:30

350

151.6

CHIX

00383426132TRLO0.1.1

21/12/2023

15:47:17

578

151

BATE

00383430747TRLO0.1.1

21/12/2023

15:47:17

578

151.2

CHIX

00383430746TRLO0.1.1

21/12/2023

15:47:17

395

151

BATE

00383430748TRLO0.1.1

21/12/2023

15:47:17

354

151

AQXE

00383430750TRLO0.1.1

21/12/2023

15:47:17

477

151.2

XLON

00383430749TRLO0.1.1

21/12/2023

15:47:17

358

151

AQXE

00383430751TRLO0.1.1

21/12/2023

15:47:17

1728

151.2

XLON

00383430753TRLO0.1.1

21/12/2023

15:47:17

107

151.2

XLON

00383430752TRLO0.1.1

21/12/2023

15:47:17

189

151

TRQX

00383430754TRLO0.1.1

21/12/2023

15:47:17

189

151

TRQX

00383430755TRLO0.1.1

21/12/2023

15:51:29

1110

150.4

CHIX

00383432741TRLO0.1.1

21/12/2023

15:51:29

2312

150.4

XLON

00383432742TRLO0.1.1

21/12/2023

15:51:41

189

150.6

TRQX

00383432837TRLO0.1.1

21/12/2023

15:53:34

21

150.6

BATE

00383433681TRLO0.1.1

21/12/2023

15:53:34

189

150.8

BATE

00383433682TRLO0.1.1

21/12/2023

16:03:22

8

151

AQXE

00383438358TRLO0.1.1

21/12/2023

16:03:52

8

150.8

AQXE

00383438538TRLO0.1.1

21/12/2023

16:19:47

213

151

AQXE

00383446136TRLO0.1.1

21/12/2023

16:29:24

137

151

AQXE

00383451700TRLO0.1.1

21/12/2023

16:29:45

350

151

AQXE

00383452193TRLO0.1.1

21/12/2023

16:29:49

754

150.8

BATE

00383452365TRLO0.1.1

21/12/2023

16:29:49

309

150.8

BATE

00383452366TRLO0.1.1

21/12/2023

16:29:49

470

150.8

CHIX

00383452367TRLO0.1.1

21/12/2023

16:29:49

557

150.8

CHIX

00383452368TRLO0.1.1

21/12/2023

16:29:49

547

150.8

CHIX

00383452370TRLO0.1.1

21/12/2023

16:29:49

4

150.8

CHIX

00383452369TRLO0.1.1

21/12/2023

16:29:51

1953

150.6

XLON

00383452412TRLO0.1.1

21/12/2023

16:29:51

192

150.6

TRQX

00383452413TRLO0.1.1

21/12/2023

16:29:51

33

150.6

TRQX

00383452414TRLO0.1.1

21/12/2023

16:29:51

269

150.6

XLON

00383452415TRLO0.1.1

21/12/2023

16:29:51

64

150.6

XLON

00383452416TRLO0.1.1

21/12/2023

16:29:55

153

150.6

TRQX

00383452507TRLO0.1.1

21/12/2023

16:29:55

329

150.6

XLON

00383452508TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings